Does MR imaging improve precision in stroke thrombolysis trials?
Hackney
David B
DB
Department of Neuroradiology, Beth Israel Deaconess Medical Center, Shapiro 4th Floor, 330 Brookline Ave, Boston, MA 02215, USA. dhackney@bidmc.harvard.edu
D000818:Animals; D002986:Clinical Trials as Topic; D005341:Fibrinolysin / Q000494:pharmacology; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D007269:Injections, Intra-Arterial; D008279:Magnetic Resonance Imaging / Q000379:methods*; D010446:Peptide Fragments / Q000494:pharmacology; D051381:Rats; D020521:Stroke / Q000188:drug therapy* / Q000473:pathology*; D015912:Thrombolytic Therapy / Q000379:methods*; D010959:Tissue Plasminogen Activator / Q000494:pharmacology
D005343:Fibrinolytic Agents; D010446:Peptide Fragments; C054561:microplasmin; D010959:Tissue Plasminogen Activator; D005341:Fibrinolysin